Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCESS IUS: Liletta for Long-Term Contraception
NCT00995150Phase 3Terminated
- Sponsor
- Medicines360
- Start
- Nov 2009
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of avatrombopag in contraception (3 arms), sponsored by Medicines360. Primary endpoints: Cumulative Pearl Index at 8 years and Number of Pregnancies Per Year at 10 years. Started Nov 2009; status: terminated.
02
Drugs
avatrombopag
03
Conditions
contraception
Beyond the preview
Go deeper on NCT00995150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00995150.